- Research article
- Open Access
Haptoglobin-α1, -α2, vitamin D-binding protein and apolipoprotein C-III as predictors of etanercept drug response in rheumatoid arthritis
Arthritis Research & Therapyvolume 17, Article number: 45 (2015)
The introduction of tumor necrosis factor-alpha (TNF-α) antagonists has substantially improved patient’s clinical outcome in rheumatoid arthritis (RA). However, nearly 20% to 40% of RA patients do not respond to anti-TNF-α treatment strategies. To identify valid predictors of TNF-α antagonist response in RA, serum proteome profiles from responders (R) and non-responders (NR) to etanercept, a soluble recombinant TNF-α receptor/IgG Fc fusion protein receptor, were compared in a prospective cohort study.
In this clinical study 50 RA patients with inadequate response to conventional DMARDs were included and treated with etanercept. The primary efficacy endpoint was response according to the European League against Rheumatism (EULAR) improvement criteria. Serum samples collected prior to initiation and after six months of etanercept therapy were cleared of the most abundant major proteins by immunoaffinity chromatography. After separation by two-dimensional differential gel electrophoresis (2D-DIGE) and identification by mass spectrometry (MS) data were validated by Western blot analysis.
After six months of etanercept treatment 62% (n = 31) of RA patients achieved response. Haptoglobin-α1 (Hp-α1) and -α2 (Hp-α2) and vitamin D-binding protein (VDBP) were found to be significantly upregulated in responder sera (P ≤0.02) at study entry. In contrast, apolipoprotein C-III (ApoC-III) showed significantly higher levels in non-responders (P = 0.0162). At study end ApoA-II, Hp-α1, Hp-α2 and VDBP were identified to be expressed at significantly higher levels (P <0.05) in responder sera.
By application of clinical proteomics in immunodepleted sera we could identify and validate for the first time Hp-α1, -α2, VDBP and ApoC-III as potential biomarkers for prediction of etanercept drug response in RA.
Rheumatoid arthritis (RA) is a chronic inflammatory disease of still unknown etiology with a prevalence of about 1% in the western population leading to progressive joint deformities by cartilage destruction and bone erosion . For the pathogenesis of RA, proinflammatory cytokines – especially tumor necrosis factor alpha (TNFα) – were shown to play one of the most important roles in RA pathogenesis by stimulation of matrix metalloproteinase and proteolytic enzyme release from synoviocytes leading to local cartilage degradation and demineralization of bone in affected joints . The course of the disease is quite variable; however, about 10% of patients experience progressive disease leading to marked joint deformities and disability.
Conventional therapeutic approaches in RA are directed at a nonspecific suppression of the inflammatory process by so-called disease-modifying antirheumatic drugs (DMARDs), such as the gold standard methotrexate and leflunomide .
The introduction of biologic DMARD therapy targeting proinflammatory cytokines, especially TNFα antagonists, has substantially improved patient’s clinical outcome in RA. Different TNFα inhibitors have so far been approved for the treatment of RA. Efficacy and safety of the TNFα antagonist etanercept , a soluble recombinant TNFα receptor/IgG Fc fusion protein receptor, have been demonstrated in randomized and placebo-controlled studies. Results of subsequent clinical trials suggest that concomitant methotrexate therapy may enhance its efficacy . However, despite these beneficial effects in RA patients’ treatment outcome, high therapeutic costs and adverse drug reactions – such as severe infections, congestive heart failure, and so forth  – limit a broad application of TNFα antagonists in RA.
In addition, 20 to 40% of RA patients were previously shown not to respond to anti-TNFα treatment strategies [5,7]. Treatment failure may manifest as primary nonresponse or secondary loss of response. Several factors may account for the lack of efficacy, including different pharmacokinetics of TNFα inhibitors, development of anti-TNFα inhibitor antibodies, pharmacogenetics and inadequate concomitant DMARD therapy. However, previous studies analyzing demographic factors , baseline disease characteristics  or pharmacogenetic factors  could not so far identify valid predictors of response to anti-TNFα therapy in RA.
Recently, proteomic technologies – in particular, capillary electrophoresis or liquid chromatography coupled to electrospray ionization mass spectrometry (MS) as well as surface enhanced laser desorption/ionization time-of-flight MS together with bioinformatics tools – have successfully been employed for identification of diagnostic markers and therapeutic targets even in highly complex body fluids [11,12] as well as for identification of drug-modulated targets and response predictors . It is thus hypothesized that analysis of TNFα antagonist-modulated alterations of the molecular circuitry by serum proteomic profiling may help to identify response predictors for TNFα antagonist therapy in RA.
In this prospective clinical cohort study, proteome profiles of serum samples were compared between responders and nonresponders to etanercept treatment in RA patients to identify potential predictors of drug response.
Patients and samples
A prospective clinical study was performed at the University Medical Center Goettingen, Germany. The study was conducted in compliance with the principles laid down in the latest version of the Declaration of Helsinki and was finally approved by the local Institutional Review Board at the University Medical Center Goettingen (No. 14/12/2007).
All included patients (n = 50) met the criteria for RA established by the American College of Rheumatology  of more than 6 months’ disease duration. All RA patients had active disease defined by three or more tender joints, three or more swollen joints, physician and patient assessment of pain of at least 40 mm or more on a 10 cm visual analogue scale and morning stiffness for >1 hour, with an elevated erythrocyte sedimentation rate (>28 mm/hour) or C-reactive protein (CRP >8 mg/l). Furthermore, all RA patients had inadequate response to standard immunosuppressive therapy with methotrexate or leflunomide. Exclusion criteria comprised all contraindications against etanercept. After evaluation of all inclusion and exclusion criteria at the screening visit (V1) and written informed consent, RA patients were enrolled in the study and assigned to receive etanercept treatment (50 mg subcutaneously once per week) as TNFα antagonist therapy at the baseline visit (V2). At each visit and at trial week 4 (V3), week 8 (V4), week 12 (V5) and week 24 (V6), clinical disease activity (Disease Activity Score in 28 joints (DAS28)) , physical function (Health Assessment Questionnaire score) , vital signs and laboratory parameters including hematology, clinical chemistry and immunologic parameters as well as CRP, erythrocyte sedimentation rate, rheumatoid factor and anti-cyclic citrullinated peptide antibodies were assessed in the local laboratory. After 6 months of etanercept treatment, response was assessed according to the European League against Rheumatism improvement criteria . A major (good or moderate) response was defined as a decrease of DAS28 ≥ 1.2. Baseline characteristics of all RA patients also including cardiovascular risk factors (arterial hypertension, diabetes, tobacco use, hyperlipoproteinemia, obesity, family history) are summarized in Table 1.
For clinical proteomics, sera (10 ml) were collected from each RA patient prior to the initiation of TNFα antagonist therapy (V1 and V2, pre-treatment samples) and during the follow-up period at trial week 12 (V5) and trial week 24 (V6) (post-treatment samples). Samples were stored at –80°C until analysis.
Serum depletion and protein precipitation
For clinical proteomics, 10 ml serum samples were taken from RA patients at visits V1, V5 and V6. Sera were then subjected to high-performance liquid chromatography-based immunodepletion for high abundant proteins using Human-14® immunoaffinity columns (Agilent, Boeblingen, Germany). The depletion of high abundant proteins from sera was carried out according to the manufacturer’s protocol. Subsequently, 6 M urea was added and the samples containing the low abundant protein fractions were concentrated using Vivaspin 4® (Sartorius Stedim, Goettingen, Germany) ultrafiltration spin columns. Samples were mixed with ice-cold precipitation solution (20% trichlororacetic acid in acetone) at a ratio of 1:3. After centrifugation the protein pellets were washed with ice-cold acetone and dried for 5 minutes. The total protein concentration was estimated using the Bradford method with bovine serum albumin (1 mg/ml) as the standard  using the LAMBDA™ 25 spectrophotometer (PerkinElmer, Waltham, Massachusetts, USA).
Two-dimensional gel electrophoresis
For large-scale two-dimensional gel electrophoresis (2-DE), immobilized pH gradient strips (11 cm, pI 3 to 10, pl 5 to 8) were passively rehydrated in 185 μl solution containing 150 μg protein in a rehydration buffer (8 M urea, 1% (w/v) 3-((3-cholamidopropyl)-dimethylammonio)-1-propane sulfonate (CHAPS), 1% dithiothreitol (DTT), 0.2% ampholytes, and a trace of bromophenol blue) for 12 hours. The isoelectric focusing step was performed on the PROTEAN® IEF Cell (Bio-Rad, Hercules, California, USA). Temperature controlled at 20°C, the voltage was set to 500 V for 1 hour, increased to 1,000 V for 1 hour and 2,000 V for 1 hour, and left at 8,000 V until a total of 50,000 V hours was reached. Prior to SDS-PAGE, the immobilized pH gradient strips were each reduced for 20 minutes at room temperature in SDS equilibration buffer containing 6 M urea, 30% glycerol, 2% SDS 0.05 M Tris–HCl, and 2% DTT on a rocking table. The strips were subsequently alkylated in the same solution with 2.5% iodacetamide substituted for DTT, and a trace of bromophenol blue. For the SDS-PAGE, 12% BisTris Criterion® precast gels (Bio-Rad) were used according to the manufacturer’s instructions. The gels were run at 150 V for 10 minutes following by 200 V until the bromophenol blue dye front had reached the bottom of the gel.
For image analysis, 2-DE gels were fixed in a solution containing 50% methanol and 12% acetic acid overnight and stained with Flamingo® fluorescent gel stain (Bio-Rad) for 5 hours. Gels were then scanned at 50 μm resolution on a Fuji FLA-5100 scanner (Fuji Photo, Kanagawa, Japan). Digitalized images were analyzed using Delta 2D 3.4 (Decodon, Greifswald, Germany). 2-DE gels were post-stained with colloidal Coomassie® (Roti-Blue; Roth, Karlsruhe, Germany) overnight to enable manual spot picking for protein identification.
Protein CyDyes minimal labeling and two-dimensional differential gel electrophoresis
To assure high data quality for two-dimensional differential gel electrophoresis (2D-DIGE), four biological replicates consisting of sera from four patients per group were collected. Serum depletion and protein precipitation were performed as described above. The resulting pellet was solubilized in labeling buffer (30 mM Tris–HCl pH 8.5, 9.5 M urea, 2% CHAPS, 10 mM phenylmethylsulfonylfluoride) and centrifuged (5 minutes, 13,000 × g), and the protein concentration of the supernatant was determined. Protein samples were labeled with CyDyes as described previously . For minimal labeling, 400 pmol amine-reactive cyanine dyes Cy3 and Cy5 were added to 50 μg proteins from responders and nonresponders, respectively. The labeling reaction was carried out at 4°C in the dark for 30 minutes and the reaction was terminated by addition of 10 nmol lysine at 4°C in the dark for 10 minutes. Equal volumes of 2× sample buffer (30 mM Tris–HCl pH 8.5, 9.5 M urea, 2% CHAPS, 10 mM phenylmethylsulfonylfluoride, 130 mM DTT and 2% ampholytes 3-10) were added. To avoid dye-specific protein labeling, every pair of protein samples from two independent depleted serum samples from the same patient were processed in duplicate while swapping the dyes. Thereby four replicate gels per patient serum were obtained. Then 50 μg internal standard consisting of a mixture of the two samples (responder and nonresponder) under investigation were labeled with 400 pmol Cy2 and included on all gels to facilitate gel matching. The three differentially labeled fractions were pooled. Rehydration buffer (8 M urea, 1% CHAPS, 13 mM DTT and 1% ampholytes 3-10) was added to make up the volume to 185 μl prior to isoelectric focusing. The 2-DE was performed as described previously . The CyDye-labeled protein gels were scanned at 50 μm resolution on a Fuji FLA-5100 scanner with excitation light at long pass 473 nm (Cy2), 575 nm (Cy3) and 635 nm (Cy5). Fluorescent images were acquired in 16-bit TIFF file format. Spot matching across gels and normalization based on the internal standard was performed with Delta2D 3.4 software. Statistical significance of protein regulation as assessed by Student’s t test was assumed for P <0.01. After post-staining with Coomassie®, differentially regulated proteins were excised and processed for identification by MS.
In-gel digestion and mass spectrometry analysis
Manually excised gel plugs were subjected to an automated platform for the identification of gel-separated proteins as described recently . An Ultraflex MALDI-TOF-TOF mass spectrometer (Bruker Daltonik, Bremen, Germany) was used to acquire both peptide mass fingerprinting and fragment ion spectra, resulting in confident protein identifications based on peptide mass and sequence information. Database searches in the Swiss-Prot primary sequence database restricted to the taxonomy Homo sapiens were performed using the MASCOT Software 2.2 (Matrix Science, London, UK). Carboxamidomethylation of Cys residues was specified as fixed modification and oxidation of Met residues as variable modifications. One trypsin-missed cleavage was allowed. Mass tolerances were set to 100 ppm for peptide mass fingerprinting searches and to 100 ppm (precursor ions) and 0.7 Da (fragment ions) for MS/MS ion searches. The minimal requirement for accepting a protein as identified was at least one peptide sequence match above identity threshold in addition to at least 20% sequence coverage in the peptide mass fingerprinting.
Western blot analysis
Validation of the 2-DE data was carried out using western blot (WB) analysis. To assure the reproducibility of the WB analysis, at least three experimental replicates from each patient’s serum were performed. Proteins (40 μg) were separated by SDS-PAGE and transferred to Hybond® ECL nitrocellulose membrane (GE Healthcare, Freiburg, Germany). Immunodetection was performed as described previously . Briefly, membranes were blocked in 5% milk for 2 hours at room temperature, followed by overnight incubation at 4°C with diluted specific primary antibody including polyclonal rabbit anti-human haptoglobin (Hp; 1:1,000), rabbit anti-human apolipoprotein (Apo) C-III antibody (Genway, San Diego, CA, USA), rabbit anti-human ApoA-II antibody (Genway) or a rabbit anti-human vitamin D-binding protein antibody (Abcam, Cambridge, UK).
After washing three times in Tris-buffered saline–Tween buffer, nitrocellulose membranes were incubated with the corresponding secondary antibody (Alexa Fluor 647 goat anti-mouse IgG antibody or Alexa Fluor 647 goat anti-rabbit IgG, 1:2,000; Molecular Probes, Darmstadt, Germany). Air-dried blot membranes were then scanned at 50 μm resolution on a Fuji FLA-5100 scanner with single laser-emitting excitation light at 635 nm.
Two-dimensional western blot
Proteins (150 μg) were separated by isoelectric focusing and SDS-PAGE as described above and transferred to Hybond® ECL nitrocellulose membrane. Immunodetection was performed as described above. Mouse monoclonal anti-vitamin D-binding protein (1:1,000; Abcam) was used as primary antibody. Molecular Probes Alexa Fluor 647 goat anti-mouse IgG antibody (1:2,000) was used as secondary antibody.
All blots were quantified using ImageJ software (Open Access Bioimaging Software, NIH, Bethesda, Maryland, USA). The data were compiled with the software package GraphPad Prism (version 4; La Jolla, California, USA). Statistical differences between patient groups (responders and nonresponders) were calculated by Student’s t test for paired and unpaired samples. Results are presented as the mean ± standard deviation of at least three independent experiments. Differences were considered statistically significant when P <0.05.
Clinical outcome of etanercept treatment in RA patients
In this prospective cohort study, 50 RA patients with high disease activity and inadequate response to standard DMARD therapy were included. After 6 months of etanercept treatment (50 mg per week), 62% (n = 31) of RA patients were judged as responders and 38% (n = 19) as nonresponders to etanercept treatment. By comparison of DAS28 scores between the baseline visit (V1) and end of study (V6), these results were also reflected by a significant reduction of DAS28 scores within the responder group (P <0.0001) (Figure 1A). Furthermore, CRP and interleukin (IL)-6 (data not shown) serum levels were significantly reduced after 6 months of etanercept therapy in responders (P = 0.036) (Figure 1B). No significant changes were observed in the nonresponder group for DAS28, CRP and IL-6 (data not shown) serum levels.
Comparative analysis of differentially expressed proteins in sera of responders and nonresponders to etanercept treatment in RA patients
To explore proteome differences between sera of responders and nonresponders, and thus to identify potential predictors for etanercept treatment outcome, sera from responders (n = 5) and nonresponders (n = 5) obtained at study entry (V1) and at the end of study (V6) were subjected to serum depletion using the Human-14® column coupled to high-performance liquid chromatography to remove the 145 most abundant serum proteins. To assess the reproducibility of the protein depletion, the same sample was processed five times over the column and data reproducibility was monitored using 2D-DIGE (see Additional file 1). After optimization of the depletion protocol, serum samples from different patients and visits were subjected to serum depletion followed by protein concentration and 2D-DIGE. Proteins found to be differentially expressed were excised and subjected to in-gel digestion and MS analyses. A total of 180 spots were identified, which resulted in 55 nonredundant proteins (see Additional files 2, 3, 4 and 5). Examination of single protein spots revealed significant differences between the protein profiles of responders and nonresponders. At baseline, five proteins were found to be significantly upregulated in responders (Figure 2A; see Additional file 6). These proteins were identified as vitamin D-binding protein (VDBP), Hp-α1, Hp-α2, vitronectin and ApoC-III. ApoA-II and ApoC-II levels were also elevated, but only significant in a small proportion of the samples. After 6 months of etanercept treatment (V6), VDBP, Hp-α2, Hp-β and α1-antitrypsin were detected at significantly higher levels in responders (Figure 2B).
Confirmation of 2D-DIGE results by western blot analysis
To confirm 2D-DIGE results, sera from responders (n = 5) and nonresponders (n = 5) were subjected to fluorescent WB analysis. As demonstrated in Figure 3, the data obtained by 2D-DIGE for Hp-α1, Hp-α2 and ApoC-III could be confirmed by WBs. In contrast, the higher levels of ApoA-II in responders compared with nonresponders seen in the 2D-DIGE analysis were found to hold true only for three patients out of five, and in two patients ApoA-II did not exhibit any significant differences in responders compared with nonresponders.
Validation of 2D-DIGE results in a larger cohort of RA patients by western blot analysis
To validate results of 2D-DIGE analyses in responders and nonresponders, one-dimensional WBs were performed for Hp-α1, Hp-α2, ApoA-II and ApoC-III in a larger cohort of RA patients (n = 31 responders and n = 19 nonresponders). Results confirmed significant upregulation of Hp-α1 and Hp-α2 in responder sera in comparison with nonresponder sera prior to etanercept treatment initiation (V1) (P = 0.0231, P = 0.0185, respectively) as well as after 6 months of therapy (V6) (P = 0.00445, P = 0.0038, respectively) (Figure 4A,B). Interestingly, analysis of Hp phenotypes revealed that the frequency of the phenotype Hp 2-2 was more common in responders, and the phenotype Hp 2-1 was found to be more common in nonresponders (Figure 4C).
In contrast to 2D-DIGE data, ApoC-III was found to be significantly upregulated in nonresponder sera prior to etanercept treatment (V1) (P = 0.0164) in comparison with responders (Figure 4D). During the course of etanercept treatment, results revealed no more significant differences between responders and nonresponders.
For ApoA-II, an upregulation of protein expression was detected in responders in comparison with nonresponders (Figure 4E). However, these results were only significant after 3 months (V5, P = 0.0114) and 6 months (V6, P = 0.0228) of therapy.
Interestingly, in the case of VDBP the 2D-DIGE revealed the presence of an extra form of the proteins in responders compared with nonresponders, as evidenced by the spot pattern on the two-dimensional gel. The additional VDBP isoform seems to have a shift in isoelectric point suggesting a posttranslational modification such as changes in glycosylation pattern. To confirm these results, two-dimensional WBs were performed and demonstrated clearly that VDBP was present in four different forms in responder sera, but in only three isoforms in nonresponder sera (Figure 5).
In this study, identification of novel biomarkers as valid predictors of etanercept drug response in RA was successfully achieved by serum proteomic profiling in responders and nonresponders.
In RA, the introduction of TNFα inhibitors as biological agents has substantially improved the patient’s long-term outcome. Low disease activity or even disease remission now represents the ultimate therapeutic goal by adoption of a treat-to-target strategy to achieve tight disease control. However, several large clinical studies have demonstrated that up to 20 to 40% of RA patients do not respond to anti-TNFα biologicals. The prediction of individual response biological treatment has thus become a major clinical challenge. The need for a personalized therapeutic strategy in RA is stressed by the fact that early effective treatment has an enormous impact on patient’s overall prognosis for disease outcome. Furthermore, TNFα inhibitors may cause serious side effects and are cost-intensive in comparison with conventional DMARD therapies.
Several previous studies have analyzed clinical, laboratory and genetic factors as potential predictors of TNFα antagonist drug response: large cohort studies have revealed that older age, low functional status and concomitant prednisolone  as well as smoking, glucocorticoid use and worse physician assessment of disease activity at baseline [11,23] are negative predictors of clinical response to TNFα antagonists, whereas treatment with concomitant DMARDs and low disability were found to be associated with good response . Heterogeneous results have been reported for the presence and titers of anti-cyclic citrullinated peptide antibodies [25,26]. Novel biomarkers such as IL-6 , IL-21  and CD11c  as well as tissue biomarkers  have only been studied in small cohorts or experimental settings. Recent progress in defining genetic factors for response by analysis of single nucleotide polymorphisms [30-32] and genome-wide association studies  yielded promising results. Furthermore, serum proteome analysis studies have been performed previously in RA patients receiving biological therapies and detected differential expression of several small proteins including apolipoproteins [34-37]. However, none of these studies could clearly identify valid predictors for TNF-alpha antagonist drug response. Thus, none of these models has so far been translated into clinical application.
In this study we analyzed potential predictors of etanercept drug response by a clinical proteomics approach in sera of responders and nonresponders. Results revealed differential regulation of small serum protein expression between responders and nonresponders prior to the initiation of etanercept treatment and after 3 and 6 months of therapy. Significant upregulation of protein expression was detected in pretreatment samples of responders for Hp-α1, Hp-α2 and VDBP. In contrast, ApoC-III levels were found to be significantly upregulated in nonresponders prior to initiation of etanercept treatment. Furthermore, significant changes of these proteins were also detected during follow-up after 6 months of therapy between responders and nonresponders. By analyzing the impact of treatment duration (0, 3 and 6 months) on the protein level within the same patient group, no significant differences could be detected between V1, V5 and V6. Differences were only significant between responders and nonresponders. This finding suggests that there is no clear correlation between the treatment duration and the serum protein levels within the same group.
Haptoglobin is a polypeptide structurally consisting of two α chains (α1 or α2) and two β chains. Hp represents an acute phase protein that is induced via proinflammatory cytokines such as IL-6, IL-1 or TNFα. According to the presence of the α1 or α2 chains, three different phenotypes (Hp 1-1, Hp 2-1, Hp 2-2) could be distinguished . Previous studies have revealed that Hp 2-2 phenotypes are genetically associated with inflammatory and autoimmune diseases . Functionally, Hp binds free hemoglobin and thus represents a marker for hemolysis. Furthermore, Hp was shown previously to exert additional anti-oxidative, anti-inflammatory and immunoregulatory effects: owing to the structural similarity with 7S immunoglobulin, Hpα may suppress cellular immune responses. In addition, Hp was shown to restore homeostasis after inflammatory processes  and to bind on activated macrophages, thus leading to the inhibition of TNFα production . In this study, responders were characterized by a significant upregulation of Hpα1 and Hpα2 production prior to the initiation and after 6 months of etanercept therapy in RA. These findings may support the hypothesis that Hpα chains may support anti-inflammatory effects of etanercept in RA. Responders may profit from upregulated Hpα chain expression in RA prior to and during the course of etanercept therapy. Furthermore, the Hp 2-2 phenotypes were found to be more common in responders, whereas Hp 2-1 were mainly detected in the nonresponder group. Upregulation of Hpα1 and Hpα2 expression and Hp phenotype thus may represent valid markers for prediction of response to etanercept therapy in RA.
ApoC-III is a small protein containing 79 amino acids that resides on the surface of lipoproteins. Physiological functions of ApoC-III include the inhibition of lipoprotein lipase and hepatic lipase. ApoC-III thus represents a major regulator of lipolysis. In consequence, elevated ApoC-III levels have been detected in patients with hypertriglyceridemia . Furthermore, genetic variation studies have revealed that distinct ApoC-III haplotypes predispose for a higher risk of coronary heart disease and diabetes mellitus. In addition to these effects on lipolysis, there is emerging scientific evidence that ApoC-III exerts proinflammatory effects on both monocytes and endothelial cells during the pathogenesis of atherosclerosis: ApoC-III was previously shown to induce the expression of intercellular adhesion molecule-1 and vascular adhesion molecule-1 in endothelial cells . Furthermore, ApoC-III was found to augment arterial inflammation by stimulating the adherence of peripheral monocytes to endothelial cells  and to initiate the transcription of proinflammatory cytokines via activation of nuclear factor-κB in monocytes . In this study, significantly elevated ApoC-III serum levels were detected in the nonresponder group in comparison with responders prior to initiation of etanercept therapy. In correlation with previous findings concerning cardiovascular comorbidity, nonresponders in our study population were characterized by a higher (but nonsignificant) incidence of concomitant cardiovascular risk factors (Table 1). Upregulation of ApoC-III in nonresponders may counteract therapeutic effects of etanercept by antagonism of TNFα blockade and thus may be responsible for treatment failure in this RA patient group. This hypothesis may be supported by the finding that ApoC-III levels positively correlate with IL-6 serum levels at study entry (data not shown). This correlation was statistically not significant, however, perhaps due to the limited number of samples analyzed in this study.
VDBP is a multifunctional α2-globulin (50 to 52 kDa). Its main functional role is the binding and transport of vitamin D metabolites to effector cells. Owing to the fact that vitamin D3 is essential for bone metabolism and exerts immunomodulatory effects via inhibition of T-helper cell type 1 T-cell responses and proinflammatory cytokine action (IL-1, IL-6), VDBP is thought to support positive effects on both bone metabolism and immune system by induction of anti-inflammatory pathways . Furthermore, VDBP is essential for G-actin binding to inhibit uncontrolled intravascular G-actin polymerization after cellular tissue damage, and thus to inhibit microembolism and organ dysfunction after cellular necrosis.
In responders, VDBP was detected at significantly elevated levels in this study. It is thus hypothesized that in responders VDBP and etanercept may exert synergistic effects on bone metabolism and immune function in RA. In this respect, responders characterized by elevated VDBP levels may profit from a higher vitamin D3 availability and G-actin binding capacity after cellular necrosis in comparison with nonresponders. This hypothesis may be supported by the finding of a negative correlation between VDBP and IL-6 serum levels at study entry (data not shown); however, the correlation analysis was again statistically not significant. The small number of serum samples analyzed and the large number of factors (cytokines, hormones and concomitant diseases) known to influence IL-6 serum levels may account for this finding.
Interestingly, a posttranslational modification of VDBP was detected in responders by two-dimensional WB as compared with nonresponders. The pattern of this modification suggests changes in glycosylation status for responders. Previous studies have demonstrated that glycosylation of VDBP leads to the production of macrophage activating factor via T-cell and B-cell associated enzymes . Macrophage activating factor production was shown to induce proinflammatory, anti-angiogenic, anti-tumorous and anti-proliferative effects . It is thus hypothesized that, in nonresponders characterized by glycosylated isoforms of VDBP, treatment failure of etanercept may be due to the overproduction of macrophage activating factor. However, this hypothesis still has to be analyzed and validated in future experimental studies.
In this study, several biomarkers for response to etanercept treatment could be identified by application of a clinical proteomics approach. However, a small sample size represents a limitation of the study. Furthermore, limitations of the clinical proteomics approach in identifying biomarkers are demonstrated and underline the necessity of proteomics data validation.
By application of a clinical proteomics approach, our study demonstrates that small serum proteins such as Hp-α1, Hp-α2, VDBP and ApoC-III may serve as valid predictors for etanercept drug response in RA. Further studies in larger and independent cohorts are required to confirm the study results and to develop the best model with the greatest predictive accuracy for treatment response to etanercept in RA.
Disease Activity Score in 28 joints
two-dimensional gel electrophoresis
two dimensional differential gel electrophoresis
disease-modifying antirheumatic drug
tumor necrosis factor alpha
vitamin D-binding protein
Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet. 2001;358:903–11.
Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med. 2001;344:907–16.
O’Dell JR. Therapeutic strategies for rheumatoid arthritis. N Engl J Med. 2004;350:2591–602.
Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000;343:1586–93.
Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004;363:675–81.
Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295:2275–85.
Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 2005;52:3381–90.
Hyrich KL, Watson KD, Silman AJ, Symmons DP. British Society for Rheumatology Biologics Register. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology. 2006;45:1558–65.
Baumgartner SW, Fleischmann RM, Moreland LW, Schiff MH, Markenson J, Whitmore JB. Etanercept (Enbrel) in patients with rheumatoid arthritis with recent onset versus established disease: improvement in disability. J Rheumatol. 2004;31:1532–7.
Kooloos WM, de Jong DJ, Huizinga TW, Guchelaar HJ. Potential role of pharmacogenetics in anti-TNF treatment of rheumatoid arthritis and Crohn’s disease. Drug Discov Today. 2007;12:125–31.
Tolson J, Bogumil R, Brunst E, Beck H, Elsner R, Humeny A, et al. Serum protein profiling by SELDI mass spectrometry: detection of multiple variants of serum amyloid alpha in renal cancer patients. Lab Invest. 2004;84:845–56.
Dihazi H, Müller GA, Lindner S, Meyer M, Asif AR, Oellerich M, et al. Characterization of diabetic nephropathy by urinary proteomic analysis: identification of a processed ubiquitin form as a differentially excreted protein in diabetic nephropathy patients. Clin Chem. 2007;53:1636–45.
Ma Y, Ding Z, Qian Y, Shi X, Castranova V, Harner EJ, et al. Predicting cancer drug response by proteomic profiling. Clin Cancer Res. 2006;12:4583–9.
Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–24.
van der Heijde DM, van’t Hof MA, van Riel PL, Theunisse LA, Lubberts EW, van Leeuwen MA, et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis. 1990;49:916–20.
Fries JF. The assessment of disability: from first to future principles. Br J Rheumatol. 1983;22:48–58.
Van Gestel AM, Haagsma CJ, van Riel PL. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum. 1998;41:1845–50.
Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of proteins utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248–54.
Jahn O, Hesse D, Reinelt M, Kratzin HD. Technical innovations for the automated identification of gel-separated proteins by MALDI-TOF mass spectrometry. Anal Bioanal Chem. 2006;386:92–103.
Patzig J, Jahn O, Tenzer S, Wichert SP, de Monasterio-Schrader P, Rosfa S, et al. Quantitative and integrative proteome analysis of peripheral nerve myelin identifies novel myelin proteins and candidate neuropathy loci. J Neurosci. 2011;31:16369–86.
Dihazi H, Dihazi GH, Nolte J, Meyer S, Jahn O, Müller GA, et al. Multipotent adult germline stem cells and embryonic stem cells: comparative proteomic approach. J Proteome Res. 2009;8:5497–510.
Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT, et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum. 2010;62:22–32.
Canhão H, Rodrigues AM, Mourão AF, Martins F, Santos MJ, Canas-Silva J, et al. Comparative effectiveness and predictors of response to tumor necrosis factor inhibitor therapies in rheumatoid arthritis. Rheumatology. 2012;51:2020–6.
Kristensen LE, Kapetanovic MC, Gülfe A, Söderlin M, Saxne T, Geborek P. Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology. 2008;47:495–9.
Braun-Moscovici Y, Markovits D, Zinder O, Schapira D, Rozin A, Ehrenburg M, et al. Anti-cyclic citrullinated protein antibodies as a predictor of response to anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis. J Rheumatol. 2006;33:497–500.
Dejaco C, Duftner C, Klotz W, Schirmer M, Herold M. Third generation anti-cyclic citrullinated peptide antibodies do not predict anti-TNF-alpha treatment response in rheumatoid arthritis. Rheumatol Int. 2010;30:451–4.
Zivojinovic S, Pejnovic N, Sefik-Bukilica M, Kovacevic L, Soldatovic I, Bugarski D, et al. Effects of TNF inhibitors on innate inflammatory and Th17 cytokines in stimulated whole blood from rheumatoid arthritis patients. Inflammopharmacology. 2012;20:323–30.
Stuhlmüller B, Häupl T, Hernandez MM, Grützkau A, Kuban RJ, Tandon N, et al. CD11c as a transcriptional biomarker to predict response to anti-TNF monotherapy with adalimumab in patients with rheumatoid arthritis. Clin Pharmacol Ther. 2010;87:311–21.
Wijbrandts CA, Dijkgraaf MG, Kraan MC, Vinkenoog M, Smeets TJ, Dinant H, et al. The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumor necrosis factor alpha expression in the synovium. Ann Rheum Dis. 2008;67:1139–44.
Sarsour K, Greenberg J, Johnston JA, Nelson DR, O’Brien LA, Oddoux C, et al. The role of the FcGRIIIa polymorphism in modifying the association between treatment and outcome in patients with rheumatoid arthritis treated with rituximab versus TNF-α antagonist therapies. Clin Exp Rheumatol. 2013;31:189–94.
Plant D, Prajapati R, Hyrich KL, Morgan AW, Wilson AG, Isaacs JD, et al. Replication of association of the PTPRC gene with response to anti-tumor necrosis factor therapy in a large UK cohort. Arthritis Rheum. 2012;64:665–70.
Coulthard LR, Taylor JC, Eyre S, Biologics in Rheumatoid Arthritis Genetics and Genomics, Robinson JI, Wilson AG, et al. Genetic variants within the MAP kinase signalling network and anti-TNF treatment response in rheumatoid arthritis patients. Ann Rheum Dis. 2011;70:98–103.
Plant D, Bowes J, Potter C, Hyrich KL, Morgan AW, Wilson AG, et al. Genome-wide association study of genetic predictors of anti-tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci. Arthritis Rheum. 2011;63:645–53.
Trocmé C, Marotte H, Baillet A, Pallot-Prades B, Garin J, Grange L, et al. Apolipoprotein A-I and platelet factor 4 are biomarkers for infliximab response in rheumatoid arthritis. Ann Rheum Dis. 2009;68:1328–33.
Sekigawa I, Yanagida M, Iwabuchi K, Kaneda K, Kaneko H, Takasaki Y, et al. Protein biomarker analysis by mass spectrometry in patients with rheumatoid arthritis receiving anti-tumor necrosis factor-alpha antibody therapy. Clin Exp Rheumatol. 2008;26:261–7.
Yanagida M, Jung G, Tanaka Y, Sone S, Fujishiro M, Ikeda K, et al. Serum proteome analysis in patients with rheumatoid arthritis receiving therapy with etanercept, a chimeric tumor necrosis factor-alpha receptor. Int J Rheum Dis. 2012;15:486–95.
Yanagida M, Kawasaki M, Fujishiro M, Miura M, Ikeda K, Nozawa K, et al. Serum proteome analysis in patients with rheumatoid arthritis receiving therapy with tocilizumab: an anti-interleukin-6 receptor antibody. Biomed Res Int. 2013;2013:607137.
Mikkat S, Koy C, Ulbrich M, Ringel B, Glocker MO. Mass spectrometric protein structure characterization reveals cause of migration differences of haptoglobin alpha chains in two-dimensional gel electrophoresis. Proteomics. 2004;4:3921–32.
Langlois MR, Delanghe JR. Biological and clinical significance of haptoglobin polymorphism in humans. Clin Chem. 1996;42:1589–600.
Huntoon KW, Wang Y, Eppolito CA, Barbour KW, Berger FG, Shrikant PA, et al. The acute phase protein haptoglobin regulates host immunity. J Leukoc Biol. 2008;84:170–81.
Theilgard-Mönch K, Jacobsen LC, Nielsen MJ, Rasmussen T, Udby L, Gharib M, et al. Haptoglobin is synthesized during granulocyte differentiation, stored in specific granules, and released by neutrophils in response to activation. Blood. 2006;108:353–61.
Cohn JS, Tremblay M, Batal R, Jacques H, Rodriguez C, Steiner G, et al. Increased apoC-III production is a characteristic feature of patients with hypertriglyceridemia. Atherosclerosis. 2004;177:137–45.
Kawakami A, Aikawa M, Alcaide P, Luscinskas FW, Libby P, Sacks FM. Apolipoprotein CIII induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytic cells. Circulation. 2006;114:681–7.
Kawakami A, Aikawa M, Libby P, Alcaide P, Luscinskas FW, Sacks FM. Apolipoprotein CIII in apolipoprotein B lipoproteins enhances the adhesion of human monocytic cells to endothelial cells. Circulation. 2006;113:691–700.
Sharif O, Bolshakow VN, Raines S, Newham P, Perkins ND. Transcriptional profiling of the LPS-induced NF-kappaB response in macrophages. BMC Immunol. 2007;8:1.
Speeckaert M, Huang G, Delanghe JR, Taes YE. Biological and clinical aspects of the vitamin D binding protein (Gc-globulin) and its polymorphism. Clin Chim Acta. 2006;372:33–42.
Rehder DS, Nelson RW, Borges CR. Glycosylation status of vitamin D binding protein in cancer patients. Protein Sci. 2009;18:2036–42.
Kanda S, Mochizuki Y, Migata Y, Kanetake H, Yamamoto N. Effects of vitamin D(3)-binding protein-derived macrophage activating factor (GcMAF) on angiogenesis. J Natl Cancer Inst. 2002;94:1311–9.
This work was supported by a grant of the Pfizer (formerly Wyeth BioPharma) Research Initiative 2007. Clinical assistance during the whole study period by the study nurse Gabriela Hermanns is gratefully acknowledged.
The authors declare that they have no competing interests.
SB conceived the study and made substantial contributions to the acquisition of data, analysis and interpretation of data and drafted the manuscript. SP was involved in patient recruitment of the study, participated in its coordination and revised the manuscript. KR, MM and HD carried out clinical proteomics, performed the statistical analysis and revised the manuscript. CAM, GAM, OJ and TF were involved in analysis and interpretation of data and critically revised the manuscript. All authors read and approved the final manuscript.
A figure showing serum depletion by immunoaffinity chromatography. Serum samples were cleared of the 14 most abundant major proteins by immunoaffinity chromatography using Human-14® immunoaffinity columns according to the manufacturer’s protocol. Serum proteome gels before depletion (upper panel), depleted high abundant proteins (lower panel left) and low abundant proteins (lower panel right) are demonstrated.
Figure showing 2D-DIGE analysis of RA patients’ sera. For 2D-DIGE, 50 μg proteins (from each sample) labeled with the appropriate dye were loaded on an 11 cm immobilized pH gradient strip with a linear pH gradient pI of 5 to 8 for isoelectric focusing, 12% SDS-polyacrylamide gels were used for the SDS-PAGE. The gels were compared with Delta 2D (Decodon). Protein identification was carried out using MS and data bank search. Blue spots, proteins in responder (R) sera; orange spots, proteins in nonresponder (NR) sera; black spots, proteins present in both R and NR sera. (A) 2D-DIGE from sera taken prior to etanercept treatment (V1), (B) 2D-DIGE from sera taken 3 months (V5) after start of treatment, (C) 2D-DIGE from sera obtained at 6 months (V6) after initiation of etanercept therapy.
A table presenting MS analysis and protein identification of differentially expressed proteins at V1.
A table presenting MS analysis and protein identification of differentially expressed proteins at V6.
A table presenting MS analysis and protein identification of differentially expressed proteins at V5.
A table presenting spot quantification at baseline (V1) in responders and nonresponders.